Neurocrine Biosciences Receives “Buy” Rating from Jefferies Group (NBIX)
Neurocrine Biosciences (NASDAQ:NBIX)‘s stock had its “buy” rating reaffirmed by research analysts at Jefferies Group in a report released on Tuesday, American Banking News reports.
Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded down 29.10% on Tuesday, hitting $11.84. 3,761,799 shares of the company’s stock traded hands. Neurocrine Biosciences has a one year low of $6.72 and a one year high of $16.74. The stock’s 50-day moving average is $14.71 and its 200-day moving average is $12.88. The company’s market cap is $794.0 million.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Thursday, July 25th. The company reported ($0.18) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.20) by $0.02. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.77 million. During the same quarter in the prior year, the company posted ($0.01) earnings per share. The company’s quarterly revenue was down 93.1% on a year-over-year basis. Analysts expect that Neurocrine Biosciences will post $-0.78 EPS for the current fiscal year.
A number of other firms have also recently commented on NBIX. Analysts at Oppenheimer raised their price target on shares of Neurocrine Biosciences (NASDAQ:NBIX) from $16.00 to $19.00 in a research note to investors on Tuesday, September 3rd. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital initiated coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a research note to investors on Friday, August 30th. They set a “buy” rating and a $18.00 price target on the stock. Finally, analysts at Deutsche Bank raised their price target on shares of Neurocrine Biosciences (NASDAQ:NBIX) from $15.00 to $25.00 in a research note to investors on Thursday, August 29th. They now have a “buy” rating on the stock.
One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $17.57.
In other Neurocrine Biosciences news, Insider Christopher Flint Obrien sold 5,000 shares of the stock on the open market in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $16.00, for a total transaction of $80,000.00. Following the sale, the insider now directly owns 94,794 shares in the company. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Neurocrine Biosciences, Inc (NASDAQ:NBIX) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.